INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 149 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $555,000 | +20.9% | 6,624 | -11.2% | 0.00% | 0.0% |
| Q1 2018 | $459,000 | -77.9% | 7,462 | -79.0% | 0.00% | -77.8% |
| Q4 2017 | $2,079,000 | -20.8% | 35,582 | -21.3% | 0.01% | -35.7% |
| Q3 2017 | $2,625,000 | -31.6% | 45,220 | +42.6% | 0.01% | -36.4% |
| Q2 2017 | $3,840,000 | +19.6% | 31,715 | +11.7% | 0.02% | -18.5% |
| Q1 2017 | $3,211,000 | -18.4% | 28,391 | -21.6% | 0.03% | -3.6% |
| Q4 2016 | $3,933,000 | +54.0% | 36,206 | +133.4% | 0.03% | +47.4% |
| Q3 2016 | $2,554,000 | +33.6% | 15,515 | +15.8% | 0.02% | +26.7% |
| Q2 2016 | $1,912,000 | +1.6% | 13,400 | +6.3% | 0.02% | +114.3% |
| Q4 2015 | $1,882,000 | -30.8% | 12,600 | -23.2% | 0.01% | -53.3% |
| Q3 2015 | $2,720,000 | +2.4% | 16,400 | +49.1% | 0.02% | 0.0% |
| Q2 2015 | $2,655,000 | +224.6% | 11,000 | +279.3% | 0.02% | +150.0% |
| Q1 2015 | $818,000 | -54.5% | 2,900 | -61.8% | 0.01% | -64.7% |
| Q2 2014 | $1,799,000 | +581.4% | 7,600 | +850.0% | 0.02% | +750.0% |
| Q1 2014 | $264,000 | – | 800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |